University of Tokyo-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:University of Tokyo - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013601
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
The University of Tokyo (UTokyo) is a research university that offers undergraduate, graduate, professional and distance learning programs. The university offers courses in the field of science, agriculture, economics, law, medicine, engineering, pharmaceutical sciences, and others. It also gets funding from Japanese and foreign companies for various collaborative research projects. UTokyo partners with other institute to provide educational services. The university operates through its academic centers such as Asian Natural Environmental Science Center, Biotechnology Research Center, Center for Research and Development of Higher Education, Center for Spatial Information Science, Cryogenic Research Center, and others. UTokyo is headquartered in Bunkyo-Ku, Japan.

University of Tokyo – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
University of Tokyo, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
University of Tokyo, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
University of Tokyo, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
University of Tokyo, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
University of Tokyo, Medical Devices Deals, 2011 to YTD 2017 9
University of Tokyo, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
University of Tokyo, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Astellas Pharma Enters into Agreement with Institute of Medical Science, the University of Tokyo 11
IMSUT and Astellas Pharma Enter into Agreement 12
Sanofi Enters into Drug Discovery Agreement with University of Tokyo 13
University of Tokyo Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 14
Shimadzu Enters Into Research Agreement With University of Tokyo 15
TransGenic Enters Into Collaboration With Dainippon Sumitomo And The University of Tokyo 16
Licensing Agreements 17
TransGenic Enters into Licensing Agreement with University of Tokyo 17
BrightPath Biotherapeutics Enters into Licensing Agreement with University of Tokyo 18
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 19
Vedanta Biosciences Enters into Licensing Agreement with Riken, University of Tokyo, and Azabu University 21
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 22
University of Tokyo – Key Competitors 23
University of Tokyo – Key Employees 24
University of Tokyo – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Product News 26
02/10/2016: Daiichi Sankyo Joint Development Product Designated Under “SAKIGAKE Designation System” 26
Product Approvals 27
Jul 11, 2017: Oncolytic Virus G47delta (DS-1647) designated as Orphan Drug under Orphan Drug/Medical Device Designation System 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
University of Tokyo, Pharmaceuticals & Healthcare, Key Facts 2
University of Tokyo, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
University of Tokyo, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
University of Tokyo, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
University of Tokyo, Deals By Therapy Area, 2011 to YTD 2017 8
University of Tokyo, Medical Devices Deals, 2011 to YTD 2017 9
University of Tokyo, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Astellas Pharma Enters into Agreement with Institute of Medical Science, the University of Tokyo 11
IMSUT and Astellas Pharma Enter into Agreement 12
Sanofi Enters into Drug Discovery Agreement with University of Tokyo 13
University of Tokyo Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 14
Shimadzu Enters Into Research Agreement With University of Tokyo 15
TransGenic Enters Into Collaboration With Dainippon Sumitomo And The University of Tokyo 16
TransGenic Enters into Licensing Agreement with University of Tokyo 17
BrightPath Biotherapeutics Enters into Licensing Agreement with University of Tokyo 18
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 19
Vedanta Biosciences Enters into Licensing Agreement with Riken, University of Tokyo, and Azabu University 21
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 22
University of Tokyo, Key Competitors 23
University of Tokyo, Key Employees 24
University of Tokyo, Subsidiaries 25

★海外企業調査レポート[University of Tokyo-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Great Plains Energy Incorporated:企業の戦略・SWOT・財務情報
    Great Plains Energy Incorporated - Strategy, SWOT and Corporate Finance Report Summary Great Plains Energy Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Fred Hutchinson Cancer Research Center:企業のM&A・事業提携・投資動向
    Fred Hutchinson Cancer Research Center - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fred Hutchinson Cancer Research Center Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …
  • Noble Life Sciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Noble Life Sciences Inc (Noble Life Sciences) is a contract research organization that offers drug, vaccine, and medical device development services. The company provides preclinical services such as analytical and laboratory services, disease and animal models, drug pharmacology and explora …
  • CIGNA Corporation:企業の戦略・SWOT・財務情報
    CIGNA Corporation - Strategy, SWOT and Corporate Finance Report Summary CIGNA Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Gritstone Oncology Inc-製薬・医療分野:企業M&A・提携分析
    Summary Gritstone Oncology Inc (Gritstone) is a cancer immunotherapy company which focuses on the development of personalized cancer therapeutics. The company primarily concentrates on identifying and deploying the therapeutic neo-antigens from individual patients’ tumors for the development of nove …
  • Vail Resorts Inc:企業の戦略・SWOT・財務情報
    Vail Resorts Inc - Strategy, SWOT and Corporate Finance Report Summary Vail Resorts Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • BioMotiv LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary BioMotiv LLC (BioMotiv) is a therapeutics licensing and development service provider. The company offers therapeutics across wide disease areas including proteins, small molecules, antibodies, and nucleotides. It portfolio includes psoriasis, inflammatory bowel diseases, cancer, retinitis pi …
  • YGM Trading Ltd.:戦略・SWOT・企業財務分析
    YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report Summary YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • China Sunergy Co., Ltd.:電力:M&Aディール及び事業提携情報
    Summary China Sunergy Co., Ltd. (China Sunergy) is a leading manufacturer of solar cells and modules. It produces mono-crystalline and multi-crystalline silicon solar cells. The company offers standard P-type solar cells and HP solar cells; and selective emitter cells. China Sunergy also invests in, …
  • Liberty Media Corp (BATRA):企業の財務・戦略的SWOT分析
    Liberty Media Corp (BATRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • ManpowerGroup Inc (MAN):企業の財務・戦略的SWOT分析
    ManpowerGroup Inc (MAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Merck & Co Inc (MRK)-製薬・医療分野:企業M&A・提携分析
    Summary Merck & Co Inc (Merck) focuses on the discovery, development, manufacture and commercialization of prescription pharmaceuticals, biologic therapies, vaccines and animal healthcare products. It offers prescription products for treating cardiovascular, cancer, immunology, infectious, respirato …
  • AdvanDx Inc-医療機器分野:企業M&A・提携分析
    Summary AdvanDx Inc (AdvanDx), a subsidiary of OpGen Inc is a healthcare solution provider that offers rapid and accurate molecular diagnostic tests for identification of pathogens causing critical infections in hospitalized patients. The company operates molecular testing of positive blood cultures …
  • Alere Toxicology Plc:企業の戦略的SWOT分析
    Alere Toxicology Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Meiji Holdings Co Ltd (2269):企業の財務・戦略的SWOT分析
    Meiji Holdings Co Ltd (2269) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Axxam SpA-製薬・医療分野:企業M&A・提携分析
    Summary Axxam SpA (Axxam) is a partner research organization that provides drug discovery services. The organization offers drug discovery services such as molecular biology, assay development and reagent provision, compound management, hit characterization and profiling and electrophysiology, among …
  • Limacorporate SpA:医療機器:M&Aディール及び事業提携情報
    Summary Limacorporate SpA (Lima) is a medical device company that develops, manufactures and commercializes reconstructive and fixation orthopaedic solutions. The company offers large joint primary and revision implants, extremities and fixation and promade products. It provides medical devices for …
  • Piramal Enterprises Ltd (PEL):企業の財務・戦略的SWOT分析
    Piramal Enterprises Ltd (PEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Euronet Worldwide Inc (EEFT):企業の財務・戦略的SWOT分析
    Euronet Worldwide Inc (EEFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Courtagen Life Sciences Inc-医療機器分野:企業M&A・提携分析
    Summary Courtagen Life Sciences Inc (Courtagen) is a medical device company that provides neurological treatment solutions. The company’s products include neuro-development panels, lysosomal disorder panels, syndrome panels, comprehensive epilepsy panels, focus epilepsy panels, metabolism test equip …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆